WO2012148246A3 - Procédé de préparation de sitagliptine - Google Patents

Procédé de préparation de sitagliptine Download PDF

Info

Publication number
WO2012148246A3
WO2012148246A3 PCT/KR2012/003381 KR2012003381W WO2012148246A3 WO 2012148246 A3 WO2012148246 A3 WO 2012148246A3 KR 2012003381 W KR2012003381 W KR 2012003381W WO 2012148246 A3 WO2012148246 A3 WO 2012148246A3
Authority
WO
WIPO (PCT)
Prior art keywords
sitagliptin
preparation
isopropylmagnesium
halo
mild
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2012/003381
Other languages
English (en)
Other versions
WO2012148246A2 (fr
Inventor
Soo Jin Choi
Byung Goo Lee
Seong Soo Oh
Yong Tae Kim
Jin Yong Eo
Hung Sop Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daewoong Pharmaceutical Co Ltd
Original Assignee
Daewoong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daewoong Pharmaceutical Co Ltd filed Critical Daewoong Pharmaceutical Co Ltd
Publication of WO2012148246A2 publication Critical patent/WO2012148246A2/fr
Publication of WO2012148246A3 publication Critical patent/WO2012148246A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un procédé de préparation de sitagliptine et, plus particulièrement, un procédé de préparation de sitagliptine utilisant de l'acide L-aspartique ayant une structure d'acide aminé (R)-bêta par formation douce d'amide, grâce à l'utilisation d'halogénoisopropylmagnésium industriellement applicable et par l'élimination d'un groupe protecteur d'amine à l'aide de Pd/C et de H2 et la réduction de carbonyle à l'aide d'un agent réducteur.
PCT/KR2012/003381 2011-04-29 2012-04-30 Procédé de préparation de sitagliptine Ceased WO2012148246A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20110041167 2011-04-29
KR10-2011-0041167 2011-04-29

Publications (2)

Publication Number Publication Date
WO2012148246A2 WO2012148246A2 (fr) 2012-11-01
WO2012148246A3 true WO2012148246A3 (fr) 2013-01-24

Family

ID=47072966

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/003381 Ceased WO2012148246A2 (fr) 2011-04-29 2012-04-30 Procédé de préparation de sitagliptine

Country Status (2)

Country Link
KR (1) KR101414314B1 (fr)
WO (1) WO2012148246A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015162506A1 (fr) * 2014-04-21 2015-10-29 Suven Life Sciences Limited Procédé de préparation de sitagliptine et nouveaux intermédiaires
CN107129501B (zh) * 2017-05-19 2019-05-21 贵州大学 2型糖尿病药物西他列汀制备新方法
KR102589305B1 (ko) * 2021-04-22 2023-10-16 주식회사 메디켐코리아 시타글립틴 인산염의 개선된 제조방법
WO2024197478A1 (fr) * 2023-03-24 2024-10-03 浙江九洲药业股份有限公司 Intermédiaire de sitagliptine, son procédé de préparation et son utilisation
CN116283718A (zh) * 2023-03-24 2023-06-23 浙江九洲药业股份有限公司 一种西格列汀中间体及其制备方法与应用
CN116395650B (zh) * 2023-05-22 2025-03-18 安徽理工大学 一种FeP掺杂的聚三嗪碳材料及其制备方法和在选择性电容去离子电极中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110043288A (ko) * 2009-10-21 2011-04-27 한미홀딩스 주식회사 시타글립틴의 제조 방법 및 이에 사용되는 중간체

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110043288A (ko) * 2009-10-21 2011-04-27 한미홀딩스 주식회사 시타글립틴의 제조 방법 및 이에 사용되는 중간체

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
LIANG, GUI-BAI ET AL.: "Discovery of new binding elements in DPP-4 inhibition and their applications in novel DPP-4 inhibitor design", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 18, 2008, pages 3706 - 3710, XP002595544, DOI: doi:10.1016/J.BMCL.2008.05.061 *
SHAHRIPOUR, AURASH B. ET AL.: "Structure-Based Design of Caspase-1 Inhibitor Containing a Diphenyl Ether Sulfonamide", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 11, 2001, pages 2779 - 2782, XP002498971, DOI: doi:10.1016/S0960-894X(01)00573-X *
SHAHRIPOUR, AURASH B. ET AL.: "Structure-Based Design of Nonpeptide Inhibitors of Interleukin-1 Converting Enzyme (ICE, Caspase-1)", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 10, 2002, pages 31 - 40, XP002337789, DOI: doi:10.1016/S0968-0896(01)00250-4 *
SIBRIAN-VAZQUEZ, MARTHA ET AL.: "Improving the Strategy and Performance of Molecularly Imprinted Polymers Using Cross-Linking Functional Monomers", J. ORG. CHEM., vol. 68, 2003, pages 9604 - 9611 *
TSAI, TING-YUEH ET AL.: "Rational design and synthesis of potent and long-lasting glutamic acid-based dipeptidyl peptidase IV inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 19, 2009, pages 1908 - 1912 *

Also Published As

Publication number Publication date
KR20120122988A (ko) 2012-11-07
KR101414314B1 (ko) 2014-07-01
WO2012148246A2 (fr) 2012-11-01

Similar Documents

Publication Publication Date Title
WO2012148246A3 (fr) Procédé de préparation de sitagliptine
WO2012002688A3 (fr) Procédés de traitement du syndrome des jambes sans repos
WO2014014835A3 (fr) Formes cristallines d'un inhibiteur de la prolyl hydroxylase
WO2012002687A3 (fr) Procédés de traitement du trouble bipolaire
WO2011055944A3 (fr) Procédés pour traiter un syndrome de fibromyalgie
MX2013011259A (es) Proceso de aminacion reductora para la preparacion de la dronedarona usando el compuesto intermediario de amina.
WO2012015986A3 (fr) Dérivés substitués de bioxopipéridinyl phtalimide
IN2014KN00948A (fr)
ZA201309652B (en) Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives
IL229505A0 (en) Preparations containing, methods involving and uses of unnatural amino acids related to dolastatin history
WO2011144983A3 (fr) Procédé amélioré pour la préparation de lacosamide
WO2011023382A3 (fr) Procédé de production d'un solide cristallin à partir de dérivés de l'acide glycine-n, n-diacétique à hygroscopicité suffisamment faible
WO2012146980A3 (fr) Préparation du fingolimod et ses sels
WO2010043904A3 (fr) Procédé amélioré
WO2013093931A3 (fr) Nouveaux promédicaments de médicaments phénoliques
WO2011131368A3 (fr) Procédé de préparation d'une forme galénique orale comprenant du fingolimod
WO2012042534A3 (fr) Procédés de préparation de r-sitagliptine et de ses intermédiaires
WO2012056458A3 (fr) Composés intermédiaires et procédé de préparation de fingolimod
EP2388261A3 (fr) Procédé amélioré pour la préparation de carbapenem en utilisant des intermédiaires de carbapenem et récupération du carbapenem
WO2012024100A3 (fr) Procédé de préparation de composés d'éther d'aminocyclohexyle
WO2010004588A3 (fr) Procédé pour préparer du cinacalcet et des sels acceptables sur le plan pharmaceutique de celui-ci
WO2012148148A3 (fr) Nouveau complexe d'azide de zinc et procédé de préparation de dérivés de tétrazole l'utilisant
WO2011102640A3 (fr) Procédé de préparation de sitagliptine et sels d'amines intermédiaires utilisés dans ce procédé
WO2011131370A8 (fr) Fingolimod granulé fondu
WO2014141294A3 (fr) Procédé perfectionné pour la synthèse de melphalan et de son sel chlorhydrate

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12776350

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12776350

Country of ref document: EP

Kind code of ref document: A2